Denali Therapeutics Inc (DNLI) Financial Statements

DNLI Financial Data

EBITDA$-492.55M

Revenue (TTM)$0.00

Gross Profit (TTM)$0.00

Gross Margin—

Operating Margin—

ROE-50.11%

ROA-44.37%

Debt/Equity0.03

Current Ratio9.16

FCF$-422.10M

FCF Yield-14.29%

Piotroski F-Score—

Rev/Share (TTM)—

50-Day MA$19.92

200-Day MA$17.72

Shares Outstanding0.16B

DNLI Computed Insights

FCF$-422.10M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

DNLI Financial Statements & Data

Denali Therapeutics Inc (DNLI) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Denali Therapeutics Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $0.00. Gross profit (TTM) is $0.00. EBITDA is $-492.55M. Earnings per share (EPS) is $-2.97. The P/E ratio is -5.81. Market capitalization is $2.95B.

Free cash flow (FCF) is $-422.10M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Denali Therapeutics Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.